OABI
HealthcareOmniAb, Inc.
$1.85
$-0.03 (-1.60%)
Jan 5, 2026
Price History (1Y)
Analysis
OmniAb, Inc. is a healthcare company operating in the biotechnology industry. The company has a relatively small scale with 114 employees and a market capitalization of $266.32M. The financial health of OmniAb, Inc. indicates significant challenges. The company reported net income loss of $63,668,000 in the trailing twelve months, with an EBITDA of -$47,366,000 and a free cash flow of -$7,070,375. The operating margin is -810.2%, indicating substantial operating losses. The return on equity (ROE) is -22.4% and the return on assets (ROA) is -12.7%. The company has $59.50M in cash but also carries $21.07M in debt, resulting in a debt to equity ratio of 7.59. The valuation context for OmniAb, Inc. reveals a negative forward P/E ratio of -4.43 and an EV/EBITDA of -4.90. The company's revenue growth rate is -46.3% year-over-year, indicating a decline in sales. With no dividend yield reported, the company does not distribute dividends to shareholders.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About OmniAb, Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Visit website →Key Statistics
- Market Cap
- $266.32M
- P/E Ratio
- N/A
- 52-Week High
- $4.02
- 52-Week Low
- $1.22
- Avg Volume
- 566.40K
- Beta
- 0.85
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 114